{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T03:14:47Z","timestamp":1770174887118,"version":"3.49.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Postgraduate Innovation Research and Practice Program of Anhui Medical University","award":["YJS20230135"],"award-info":[{"award-number":["YJS20230135"]}]},{"name":"Anhui Provincial Health Research Project","award":["AHWJ2024Aa20494"],"award-info":[{"award-number":["AHWJ2024Aa20494"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04383-9","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T08:36:14Z","timestamp":1767688574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A bortezomib resistance\u2013related gene signature predicts prognosis, with ARID5B downregulation associated with poor overall survival in multiple myeloma"],"prefix":"10.1007","volume":"17","author":[{"given":"Yangyang","family":"Ding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinli","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xunyi","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinjing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiong","family":"shudao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"4383_CR1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95:548\u201367. https:\/\/doi.org\/10.1002\/ajh.25791.","journal-title":"Am J Hematol"},{"key":"4383_CR2","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","volume":"385","author":"C Rollig","year":"2015","unstructured":"Rollig C, Knop S, Bornhauser M. Multiple myeloma. Lancet. 2015;385:2197\u2013208. https:\/\/doi.org\/10.1016\/S0140-6736(14)60493-1.","journal-title":"Lancet"},{"key":"4383_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1101495","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Zhang H, Lan H, Wu J, Xiao Y. CAR-T cell therapy in multiple myeloma: current limitations and potential strategies. Front Immunol. 2023;14:1101495. https:\/\/doi.org\/10.3389\/fimmu.2023.1101495.","journal-title":"Front Immunol"},{"key":"4383_CR4","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/jnci\/95.12.845","volume":"95","author":"R Twombly","year":"2003","unstructured":"Twombly R. First proteasome inhibitor approved for multiple myeloma. J Natl Cancer Inst. 2003;95:845. https:\/\/doi.org\/10.1093\/jnci\/95.12.845.","journal-title":"J Natl Cancer Inst"},{"key":"4383_CR5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","volume":"36","author":"S Gandolfi","year":"2017","unstructured":"Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG. The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev. 2017;36:561\u201384. https:\/\/doi.org\/10.1007\/s10555-017-9707-8.","journal-title":"Cancer Metastasis Rev"},{"key":"4383_CR6","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1042\/BST20140126","volume":"42","author":"MY Murray","year":"2014","unstructured":"Murray MY, Auger MJ, Bowles KM. Overcoming bortezomib resistance in multiple myeloma. Biochem Soc Trans. 2014;42:804\u20138. https:\/\/doi.org\/10.1042\/BST20140126.","journal-title":"Biochem Soc Trans"},{"key":"4383_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00218","volume":"9","author":"ML Farrell","year":"2018","unstructured":"Farrell ML, Reagan MR. Soluble and cell-cell-mediated drivers of proteasome inhibitor resistance in multiple myeloma. Front Endocrinol (Lausanne). 2018;9:218. https:\/\/doi.org\/10.3389\/fendo.2018.00218.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4383_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7. https:\/\/doi.org\/10.1186\/1471-2105-14-7.","journal-title":"BMC Bioinformatics"},{"key":"4383_CR9","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18:248\u201362. https:\/\/doi.org\/10.1016\/j.celrep.2016.12.019.","journal-title":"Cell Rep"},{"key":"4383_CR10","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s41397-021-00230-y","volume":"21","author":"W Huang","year":"2021","unstructured":"Huang W, Qian T, Huang Z, Liu Y, Cui L, Zhu P, et al. Increased expression of IFI16 predicts adverse prognosis in multiple myeloma. Pharmacogen J. 2021;21:520\u201332. https:\/\/doi.org\/10.1038\/s41397-021-00230-y.","journal-title":"Pharmacogen J"},{"key":"4383_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104961","volume":"100","author":"P Tang","year":"2024","unstructured":"Tang P, Yu Z, Sun H, Liu L, Gong L, Fang T, et al. CRIP1 involves the pathogenesis of multiple myeloma via dual-regulation of proteasome and autophagy. EBioMedicine. 2024;100:104961. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104961.","journal-title":"EBioMedicine"},{"key":"4383_CR12","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/1535-7163.MCT-12-1151","volume":"12","author":"HA Stessman","year":"2013","unstructured":"Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A, et al. Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Mol Cancer Ther. 2013;12:1140\u201350. https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-1151.","journal-title":"Mol Cancer Ther"},{"key":"4383_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.56","volume":"7","author":"AK Mitra","year":"2017","unstructured":"Mitra AK, Harding T, Mukherjee UK, Jang JS, Li Y, HongZheng R, et al. A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma. Blood Cancer J. 2017;7:e581. https:\/\/doi.org\/10.1038\/bcj.2017.56.","journal-title":"Blood Cancer J"},{"key":"4383_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-03007-4","volume":"23","author":"Z Yu","year":"2023","unstructured":"Yu Z, Qiu B, Zhou H, Li L, Niu T. Characterization and application of a lactate and branched chain amino acid metabolism related gene signature in a prognosis risk model for multiple myeloma. Cancer Cell Int. 2023;23:169. https:\/\/doi.org\/10.1186\/s12935-023-03007-4.","journal-title":"Cancer Cell Int"},{"key":"4383_CR15","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/bjh.16744","volume":"192","author":"M Zamani-Ahmadmahmudi","year":"2021","unstructured":"Zamani-Ahmadmahmudi M, Nassiri SM, Soltaninezhad F. Development of an RNA sequencing-based prognostic gene signature in multiple myeloma. Br J Haematol. 2021;192:310\u201321. https:\/\/doi.org\/10.1111\/bjh.16744.","journal-title":"Br J Haematol"},{"key":"4383_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-015-0219-5","volume":"34","author":"M Zhou","year":"2015","unstructured":"Zhou M, Zhao H, Wang Z, Cheng L, Yang L, Shi H, et al. Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma. J Exp Clin Cancer Res. 2015;34:102. https:\/\/doi.org\/10.1186\/s13046-015-0219-5.","journal-title":"J Exp Clin Cancer Res"},{"key":"4383_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48327-9","volume":"15","author":"TS Johnson","year":"2024","unstructured":"Johnson TS, Sudha P, Liu E, Becker N, Robertson S, Blaney P, et al. 1q amplification and PHF19 expressing high-risk cells are associated with relapsed\/refractory multiple myeloma. Nat Commun. 2024;15:4144. https:\/\/doi.org\/10.1038\/s41467-024-48327-9.","journal-title":"Nat Commun"},{"key":"4383_CR18","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1080\/15384101.2024.2309020","volume":"23","author":"T Luo","year":"2024","unstructured":"Luo T, Chen X, Pan W, Zhang S, Huang J. The sorafenib resistance-related gene signature predicts prognosis and indicates immune activity in hepatocellular carcinoma. Cell Cycle. 2024;23:150\u201368. https:\/\/doi.org\/10.1080\/15384101.2024.2309020.","journal-title":"Cell Cycle"},{"key":"4383_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215583","volume":"532","author":"Y Shi","year":"2022","unstructured":"Shi Y, Xu Y, Xu Z, Wang H, Zhang J, Wu Y, et al. TKI resistant-based prognostic immune related gene signature in LUAD, in which FSCN1 contributes to tumor progression. Cancer Lett. 2022;532:215583. https:\/\/doi.org\/10.1016\/j.canlet.2022.215583.","journal-title":"Cancer Lett"},{"key":"4383_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01234-2","volume":"15","author":"M Swamydas","year":"2022","unstructured":"Swamydas M, Murphy EV, Ignatz-Hoover JJ, Malek E, Driscoll JJ. Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma. J Hematol Oncol. 2022;15:17. https:\/\/doi.org\/10.1186\/s13045-022-01234-2.","journal-title":"J Hematol Oncol"},{"key":"4383_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040988","author":"LC Holthof","year":"2020","unstructured":"Holthof LC, Mutis T. Challenges for immunotherapy in multiple myeloma: bone marrow microenvironment-mediated immune suppression and immune resistance. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12040988.","journal-title":"Cancers (Basel)"},{"key":"4383_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/341430","volume":"2015","author":"WC Yang","year":"2015","unstructured":"Yang WC, Lin SF. Mechanisms of drug resistance in relapse and refractory multiple myeloma. Biomed Res Int. 2015;2015:341430. https:\/\/doi.org\/10.1155\/2015\/341430.","journal-title":"Biomed Res Int"},{"key":"4383_CR23","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1182\/blood.2022017848","volume":"141","author":"O Van Oekelen","year":"2023","unstructured":"Van Oekelen O, Nath K, Mouhieddine TH, Farzana T, Aleman A, Melnekoff DT, et al. Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy. Blood. 2023;141:756\u201365. https:\/\/doi.org\/10.1182\/blood.2022017848.","journal-title":"Blood"},{"key":"4383_CR24","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s11523-021-00827-0","volume":"16","author":"JE Frampton","year":"2021","unstructured":"Frampton JE. Isatuximab: a review of its use in multiple myeloma. Target Oncol. 2021;16:675\u201386. https:\/\/doi.org\/10.1007\/s11523-021-00827-0.","journal-title":"Target Oncol"},{"key":"4383_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10451-4","volume":"22","author":"C Koch","year":"2022","unstructured":"Koch C, Fischer NC, Puchert M, Engele J. Interactions of the chemokines CXCL11 and CXCL12 in human tumor cells. BMC Cancer. 2022;22:1335. https:\/\/doi.org\/10.1186\/s12885-022-10451-4.","journal-title":"BMC Cancer"},{"key":"4383_CR26","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/(SICI)1096-9896(199812)186:4<390::AID-PATH194>3.0.CO;2-Z","volume":"186","author":"E Di Carlo","year":"1998","unstructured":"Di Carlo E, Modesti A, Coletti A, Colombo MP, Giovarelli M, Forni G, et al. Interaction between endothelial cells and the secreted cytokine drives the fate of an IL4- or an IL5-transduced tumour. J Pathol. 1998;186:390\u20137. https:\/\/doi.org\/10.1002\/(SICI)1096-9896(199812)186:4%3c390::AID-PATH194%3e3.0.CO;2-Z.","journal-title":"J Pathol"},{"key":"4383_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01001-1","volume":"13","author":"G Roex","year":"2020","unstructured":"Roex G, Timmers M, Wouters K, Campillo-Davo D, Flumens D, Schroyens W, et al. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. J Hematol Oncol. 2020;13:164. https:\/\/doi.org\/10.1186\/s13045-020-01001-1.","journal-title":"J Hematol Oncol"},{"key":"4383_CR28","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1200\/JCO.21.01676","volume":"40","author":"Y Wang","year":"2022","unstructured":"Wang Y, Cao J, Gu W, Shi M, Lan J, Yan Z, et al. Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma. J Clin Oncol. 2022;40:2246\u201356. https:\/\/doi.org\/10.1200\/JCO.21.01676.","journal-title":"J Clin Oncol"},{"key":"4383_CR29","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, et al. GPRC5D-targeted CAR T cells for myeloma. N Engl J Med. 2022;387:1196\u2013206. https:\/\/doi.org\/10.1056\/NEJMoa2209900.","journal-title":"N Engl J Med"},{"key":"4383_CR30","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/nm.4431","volume":"23","author":"N Hosen","year":"2017","unstructured":"Hosen N, Matsunaga Y, Hasegawa K, Matsuno H, Nakamura Y, Makita M, et al. The activated conformation of integrin beta(7) is a novel multiple myeloma-specific target for CAR T cell therapy. Nat Med. 2017;23:1436\u201343. https:\/\/doi.org\/10.1038\/nm.4431.","journal-title":"Nat Med"},{"key":"4383_CR31","first-page":"5","volume":"38","author":"V Dell'Oste","year":"2015","unstructured":"Dell\u2019Oste V, Gatti D, Giorgio AG, Gariglio M, Landolfo S, De Andrea M. The interferon-inducible DNA-sensor protein IFI16: a key player in the antiviral response. New Microbiol. 2015;38:5\u201320.","journal-title":"New Microbiol"},{"key":"4383_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02409-6","volume":"21","author":"H Wang","year":"2021","unstructured":"Wang H, Xie X, Zhu J, Qi S, Xie J. Comprehensive analysis identifies IFI16 as a novel signature associated with overall survival and immune infiltration of skin cutaneous melanoma. Cancer Cell Int. 2021;21:694. https:\/\/doi.org\/10.1186\/s12935-021-02409-6.","journal-title":"Cancer Cell Int"},{"key":"4383_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05354-w","volume":"22","author":"K Lu","year":"2024","unstructured":"Lu K, Zhao Y, Li Y, Fu Z, Chen Y, Kong Y, et al. IFI16 promotes the progression of clear cell renal cell carcinoma through the IL6\/PI3K\/AKT axis. J Transl Med. 2024;22:533. https:\/\/doi.org\/10.1186\/s12967-024-05354-w.","journal-title":"J Transl Med"},{"key":"4383_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02526-8","volume":"41","author":"Z Gao","year":"2022","unstructured":"Gao Z, Xu J, Fan Y, Zhang Z, Wang H, Qian M, et al. ARPC1B promotes mesenchymal phenotype maintenance and radiotherapy resistance by blocking TRIM21-mediated degradation of IFI16 and HuR in glioma stem cells. J Exp Clin Cancer Res. 2022;41:323. https:\/\/doi.org\/10.1186\/s13046-022-02526-8.","journal-title":"J Exp Clin Cancer Res"},{"key":"4383_CR35","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10620-023-08175-x","volume":"69","author":"W Lin","year":"2024","unstructured":"Lin W, Zhao Z, Du W, Ni Z, Pan C, Fang P, et al. Interferon-Gamma-inducible protein 16 inhibits hepatocellular carcinoma via interferon regulatory factor 3 on chemosensitivity. Dig Dis Sci. 2024;69:491\u2013501. https:\/\/doi.org\/10.1007\/s10620-023-08175-x.","journal-title":"Dig Dis Sci"},{"key":"4383_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030517","author":"C Li","year":"2021","unstructured":"Li C, Wendlandt EB, Darbro B, Xu H, Thomas GS, Tricot G, et al. Genetic analysis of multiple myeloma identifies cytogenetic alterations implicated in disease complexity and progression. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13030517.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"4383_CR37","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1042\/bj2990445","volume":"299","author":"C Khoo","year":"1994","unstructured":"Khoo C, Cousins RJ. Purification and properties of rat cysteine-rich intestinal protein. Biochem J. 1994;299(2):445\u201350. https:\/\/doi.org\/10.1042\/bj2990445.","journal-title":"Biochem J"},{"key":"4383_CR38","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021110218","volume":"41","author":"J Wang","year":"2022","unstructured":"Wang J, Zhou Y, Zhang D, Zhao W, Lu Y, Liu C, et al. CRIP1 suppresses BBOX1-mediated carnitine metabolism to promote stemness in hepatocellular carcinoma. EMBO J. 2022;41:e110218. https:\/\/doi.org\/10.15252\/embj.2021110218.","journal-title":"EMBO J"},{"key":"4383_CR39","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.lfs.2018.05.054","volume":"207","author":"LZ Zhang","year":"2018","unstructured":"Zhang LZ, Huang LY, Huang AL, Liu JX, Yang F. CRIP1 promotes cell migration, invasion and epithelial-mesenchymal transition of cervical cancer by activating the Wnt\/\u03b2\u2011catenin signaling pathway. Life Sci. 2018;207:420\u20137. https:\/\/doi.org\/10.1016\/j.lfs.2018.05.054.","journal-title":"Life Sci"},{"key":"4383_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107312","volume":"130","author":"X Deng","year":"2023","unstructured":"Deng X, Zeng Y, Qiu X, Zhong M, Xiong X, Luo M, et al. CRIP1 supports the growth and migration of AML-M5 subtype cells by activating Wnt\/beta-catenin pathway. Leuk Res. 2023;130:107312. https:\/\/doi.org\/10.1016\/j.leukres.2023.107312.","journal-title":"Leuk Res"},{"key":"4383_CR41","first-page":"95","volume":"13","author":"D Wilsker","year":"2002","unstructured":"Wilsker D, Patsialou A, Dallas PB, Moran E. Arid proteins: a diverse family of DNA binding proteins implicated in the control of cell growth, differentiation, and development. Cell Growth Differ. 2002;13:95\u2013106.","journal-title":"Cell Growth Differ"},{"key":"4383_CR42","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2147\/OTT.S57023","volume":"7","author":"C Lin","year":"2014","unstructured":"Lin C, Song W, Bi X, Zhao J, Huang Z, Li Z, et al. Recent advances in the ARID family: focusing on roles in human cancer. Onco Targets Ther. 2014;7:315\u201324. https:\/\/doi.org\/10.2147\/OTT.S57023.","journal-title":"Onco Targets Ther"},{"issue":"1185\u20131201","key":"4383_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.05.026","volume":"42","author":"A Bolomsky","year":"2024","unstructured":"Bolomsky A, Ceribelli M, Scheich S, Rinaldi K, Huang DW, Chakraborty P, et al. IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. Cancer Cell. 2024;42(1185\u20131201):e1114. https:\/\/doi.org\/10.1016\/j.ccell.2024.05.026.","journal-title":"Cancer Cell"},{"key":"4383_CR44","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s41589-020-0645-3","volume":"16","author":"J Yamamoto","year":"2020","unstructured":"Yamamoto J, Suwa T, Murase Y, Tateno S, Mizutome H, Asatsuma-Okumura T, et al. ARID2 is a pomalidomide-dependent CRL4(CRBN) substrate in multiple myeloma cells. Nat Chem Biol. 2020;16:1208\u201317. https:\/\/doi.org\/10.1038\/s41589-020-0645-3.","journal-title":"Nat Chem Biol"},{"key":"4383_CR45","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1158\/1078-0432.CCR-19-0190","volume":"26","author":"H Xu","year":"2020","unstructured":"Xu H, Zhao X, Bhojwani D, E S, Goodings C, Zhang H, et al. ARID5B influences antimetabolite drug sensitivity and prognosis of acute lymphoblastic leukemia. Clin Cancer Res. 2020;26:256\u201364. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0190.","journal-title":"Clin Cancer Res"},{"key":"4383_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-127","volume":"14","author":"M Emerenciano","year":"2014","unstructured":"Emerenciano M, Barbosa TC, Lopes BA, Blunck CB, Faro A, Andrade C, et al. ARID5B polymorphism confers an increased risk to acquire specific MLL rearrangements in early childhood leukemia. BMC Cancer. 2014;14:127. https:\/\/doi.org\/10.1186\/1471-2407-14-127.","journal-title":"BMC Cancer"},{"key":"4383_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-018-0095-x","volume":"7","author":"Z Ge","year":"2018","unstructured":"Ge Z, Han Q, Gu Y, Ge Q, Ma J, Sloane J, et al. Aberrant ARID5B expression and its association with Ikaros dysfunction in acute lymphoblastic leukemia. Oncogenesis. 2018;7:84. https:\/\/doi.org\/10.1038\/s41389-018-0095-x.","journal-title":"Oncogenesis"},{"key":"4383_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02310-2","volume":"18","author":"R Cai","year":"2020","unstructured":"Cai R, Wang P, Zhao X, Lu X, Deng R, Wang X, et al. LTBP1 promotes esophageal squamous cell carcinoma progression through epithelial-mesenchymal transition and cancer-associated fibroblasts transformation. J Transl Med. 2020;18:139. https:\/\/doi.org\/10.1186\/s12967-020-02310-2.","journal-title":"J Transl Med"},{"key":"4383_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/s10142-024-01311-4","volume":"24","author":"X Jiang","year":"2024","unstructured":"Jiang X, Yin S, Yin X, Wang Y, Fang T, Yang S, et al. A prognostic marker LTBP1 is associated with epithelial mesenchymal transition and can promote the progression of gastric cancer. Funct Integr Genomics. 2024;24:30. https:\/\/doi.org\/10.1007\/s10142-024-01311-4.","journal-title":"Funct Integr Genomics"},{"key":"4383_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.117172","volume":"241","author":"B Zhao","year":"2025","unstructured":"Zhao B, Ge X, Du P, Zhang M, Jiang M, Deng M, et al. CREM-activated LTBP1 transcription promotes radioresistance and immune escape in triple-negative breast cancer. Biochem Pharmacol. 2025;241:117172. https:\/\/doi.org\/10.1016\/j.bcp.2025.117172.","journal-title":"Biochem Pharmacol"},{"key":"4383_CR51","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/ncb3613","volume":"19","author":"X Zhuang","year":"2017","unstructured":"Zhuang X, Zhang H, Li X, Li X, Cong M, Peng F, et al. Differential effects on lung and bone metastasis of breast cancer by Wnt signalling inhibitor DKK1. Nat Cell Biol. 2017;19:1274\u201385. https:\/\/doi.org\/10.1038\/ncb3613.","journal-title":"Nat Cell Biol"},{"key":"4383_CR52","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.molcel.2019.09.018","volume":"77","author":"Q Zhao","year":"2020","unstructured":"Zhao Q, Zheng K, Ma C, Li J, Zhuo L, Huang W, et al. PTPS facilitates compartmentalized LTBP1 S-nitrosylation and promotes tumor growth under hypoxia. Mol Cell. 2020;77:95-107 e105. https:\/\/doi.org\/10.1016\/j.molcel.2019.09.018.","journal-title":"Mol Cell"},{"key":"4383_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.647209","volume":"12","author":"Z Chen","year":"2021","unstructured":"Chen Z, Yu M, Yan J, Guo L, Zhang B, Liu S, et al. PNOC expressed by B cells in cholangiocarcinoma was survival related and LAIR2 could be a T cell exhaustion biomarker in tumor microenvironment: characterization of immune microenvironment combining single-cell and bulk sequencing technology. Front Immunol. 2021;12:647209. https:\/\/doi.org\/10.3389\/fimmu.2021.647209.","journal-title":"Front Immunol"},{"key":"4383_CR54","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1182\/bloodadvances.2022009387","volume":"7","author":"YT Chang","year":"2023","unstructured":"Chang YT, Chiu I, Wang Q, Bustamante J, Jiang W, Rycaj K, et al. Loss of p53 enhances the tumor-initiating potential and drug resistance of clonogenic multiple myeloma cells. Blood Adv. 2023;7:3551\u201360. https:\/\/doi.org\/10.1182\/bloodadvances.2022009387.","journal-title":"Blood Adv"},{"key":"4383_CR55","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1093\/carcin\/bgh187","volume":"25","author":"MR Velangi","year":"2004","unstructured":"Velangi MR, Matheson EC, Morgan GJ, Jackson GH, Taylor PR, Hall AG, et al. DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma. Carcinogenesis. 2004;25:1795\u2013803. https:\/\/doi.org\/10.1093\/carcin\/bgh187.","journal-title":"Carcinogenesis"},{"key":"4383_CR56","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863\u20139. https:\/\/doi.org\/10.1200\/JCO.2015.61.2267.","journal-title":"J Clin Oncol"},{"key":"4383_CR57","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3233\/CBM-230115","volume":"38","author":"T Zheng","year":"2023","unstructured":"Zheng T, Chen P, Xu Y, Jia P, Li Y, Li Y, et al. Comprehensive analysis of thirteen-gene panel with prognosis value in multiple myeloma. Cancer Biomark. 2023;38:583\u201393. https:\/\/doi.org\/10.3233\/CBM-230115.","journal-title":"Cancer Biomark"},{"key":"4383_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.778715","volume":"12","author":"J Zhang","year":"2021","unstructured":"Zhang J, He P, Wang X, Wei S, Ma L, Zhao J. A novel model of tumor-infiltrating B lymphocyte specific RNA-binding protein-related genes with potential prognostic value and therapeutic targets in multiple myeloma. Front Genet. 2021;12:778715. https:\/\/doi.org\/10.3389\/fgene.2021.778715.","journal-title":"Front Genet"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04383-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04383-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04383-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T13:57:53Z","timestamp":1770127073000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04383-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4383"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04383-9","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Ethics Committee of the Second Affiliated Hospital of Anhui Medical University (Approval No. YJ-YX2021-139). Written informed consent was obtained from all participants, and the study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Each author approved the manuscript before submission for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"226"}}